Education
About Us
Working with TipRanks
Follow Us
Dogwood Therapeutics (DWTX)
NASDAQ:DWTX
DWTX Stock Chart & Stats
$3.15
-$0.11(-4.15%)
At close: 4:00 PM EST
$3.15
-$0.11(-4.15%)
Day’s Range― - ―
52-Week Range$2.60 - $14.69
Previous CloseN/A
Volume14.38K
Average Volume (3M)1.54M
Market Cap
$93.89M
Enterprise Value-$4.37M
Total Cash (Recent Filing)$10.13M
Total Debt (Recent Filing)$174.78K
Price to Earnings (P/E)―
Beta2.51
Next Earnings
Apr 06, 2026EPS Estimate
-1.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.20
Shares Outstanding33,295,550
10 Day Avg. Volume77,367
30 Day Avg. Volume1,536,657
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.04
Price to Sales (P/S)0.00
P/FCF Ratio-0.29
Enterprise Value/Market Cap-0.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit148.52
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$21.00Price Target Upside566.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.58
Revenue Forecast (FY)$128.77M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsTopline readout from the Phase 2b Halneuron study in chemotherapy-induced neuropathic pain could meaningfully boost investor sentiment and support a re-rating if results are positive.
Pipeline Validation And External FundingExternal funding and planned clinical testing for SP16, including a safety‑focused Phase 1b study, offers independent validation of the pipeline and reduces early development risk.
Regulatory PathwayFDA guidance that provides a clear path for pivotal study design gives the company flexibility to pursue an approvable regimen and reduces regulatory uncertainty.
Bears Say
Clinical And Development RiskPositive interim updates do not guarantee final success, so remaining clinical or protocol changes could produce setbacks that pressure the stock.
Collaboration And Intellectual Property RiskCommercial prospects depend on partnerships and patent protections, and disputes or intellectual property challenges could materially constrain growth potential.
Financial And Valuation ExposureValuation is exposed to financing and market risks, so future capital needs or adverse market conditions could lead to dilution or downward pressure on the share price.
Dogwood Therapeutics News
DWTX FAQ
What was Dogwood Therapeutics’s price range in the past 12 months?
Dogwood Therapeutics lowest stock price was $2.60 and its highest was $14.69 in the past 12 months.
What is Dogwood Therapeutics’s market cap?
Dogwood Therapeutics’s market cap is $93.89M.
When is Dogwood Therapeutics’s upcoming earnings report date?
Dogwood Therapeutics’s upcoming earnings report date is Apr 06, 2026 which is in 33 days.
How were Dogwood Therapeutics’s earnings last quarter?
Dogwood Therapeutics released its earnings results on Nov 06, 2025. The company reported -$8.2 earnings per share for the quarter, missing the consensus estimate of -$1.16 by -$7.04.
Is Dogwood Therapeutics overvalued?
According to Wall Street analysts Dogwood Therapeutics’s price is currently Undervalued.
Does Dogwood Therapeutics pay dividends?
Dogwood Therapeutics does not currently pay dividends.
What is Dogwood Therapeutics’s EPS estimate?
Dogwood Therapeutics’s EPS estimate is -1.04.
How many shares outstanding does Dogwood Therapeutics have?
Dogwood Therapeutics has 33,295,550 shares outstanding.
What happened to Dogwood Therapeutics’s price movement after its last earnings report?
Dogwood Therapeutics reported an EPS of -$8.2 in its last earnings report, missing expectations of -$1.16. Following the earnings report the stock price went down -6.475%.
Which hedge fund is a major shareholder of Dogwood Therapeutics?
Currently, no hedge funds are holding shares in DWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dogwood Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.00 (566.67% Upside)
$21.00 (566.67% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
60.36%
12-Months-Change
Fundamentals
Return on Equity
-97.54%
Trailing 12-Months
Asset Growth
2559.39%
Trailing 12-Months
Company Description
Dogwood Therapeutics
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
DWTX Stock 12 Month Forecast
Average Price Target
$21.00
▲(566.67% Upside)
Technical Analysis
Marker Therapeutics
―
BioRestorative Therapies
―
Sensei Biotherapeutics
―
Bolt Biotherapeutics
―
Acurx Pharmaceuticals
―
Ownership Overview
74.31% Insiders
0.10% Mutual Funds
<0.01% Other Institutional Investors
25.53% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---